StiRx Showcases Advances in Next-Generation Immunotherapeutics at ISV Congress 2025

Boston, MA – October 2025 — StiRx, a biotechnology company pioneering next-generation biologics for sexually transmitted infections (STIs), announced the presentation of groundbreaking preclinical data on its lead monoclonal antibody program, STX-426, at the International Society for Vaccines (ISV) Congress 2025, taking place in Stellenbosch, South Africa, from October 28–30, 2025.

STX-426 is a first-in-class, long-acting monoclonal antibody (mAb) targeting Neisseria gonorrhoeae, the bacterium responsible for gonorrhea. Engineered for enhanced effector function and extended serum half-life, STX-426 has demonstrated potent bactericidal activity and superior pharmacokinetic performance in preclinical models. These findings highlight the promise of antibody-based immunoprophylaxis as a new approach to combating antibiotic-resistant infections.

In addition to the oral presentation by Dr. Davinder Gill, co-founder and CEO of StiRx, the company will present a poster describing its dual-targeting antibody platform, designed to address the limitations of single-antigen approaches by engaging complementary immune pathways for broader and more durable protection.

“Gonorrhea has the potential to become the first truly untreatable bacterial STI,” said Dr. Gill. “STX-426 exemplifies how intelligent antibody design can overcome resistance, extend protection, and bring a long-acting prophylactic option to populations at highest risk. Our work reflects StiRx’s mission to redefine what’s possible in infectious-disease prevention.”

Dr. Sanjay Ram, Professor of Medicine, University of Massachusetts Chan Medical School and co-founder of StiRx, added: “We are entering an era where antibody-based immunoprophylaxis can fundamentally change how we prevent and control bacterial STIs. Our dual-targeting strategy is designed to simultaneously engage highly conserved multiple immune pathways, providing broader and more resilient protection against evolving pathogens. By combining this with long-acting antibody engineering, we aim to create durable, resistance-sparing interventions that can make a lasting global impact.”

StiRx is committed to developing next-generation, precision-engineered immunotherapeutics that redefine prevention and treatment of sexually transmitted infectious diseases. To learn more about StiRx’s technology platform and ongoing programs, contact info@stirx.bio.